A platform technology to robustly produce monoclonal antibodies specific for complex human protein variants.
- Allows for enhanced specificity of monoclonal antibodies to human proteins.
- Enhances antibody signal and binding affinity.
Effective methods for generating antibodies that recognize human specific protein sequence polymorphisms do not currently exist. This is largely due to incomplete homology between human proteins and proteins of other species. Consequently, antibodies, in most cases, only recognize select portions of the human protein and cannot fully distinguish important human variants. Therefore, more effective means are needed to generate antibodies that can selectively recognize key domains in human proteins.
This platform technology provides a means to reliably produce monoclonal antibodies that recognize specific variants of a human antigen. It works by applying a novel cellular adjuvant to immune-tolerized transgenic mice which consequently focuses the immune response to result in a dramatic increase in the immunogenicity of cells expressing the antigen. This method is flexible and can be engineered to produce fine specificity antibodies useful for several clinical and commercial applications.